"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
Concept/Terms
Metformin- Metformin
- Dimethylguanylguanidine
- Dimethylbiguanidine
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in Harvard Catalyst Profiles by year, and whether "Metformin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1996 | 2 | 1 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 1 | 3 |
| 2000 | 2 | 2 | 4 |
| 2001 | 2 | 0 | 2 |
| 2002 | 3 | 1 | 4 |
| 2003 | 2 | 6 | 8 |
| 2004 | 6 | 3 | 9 |
| 2005 | 4 | 5 | 9 |
| 2006 | 1 | 6 | 7 |
| 2007 | 5 | 7 | 12 |
| 2008 | 2 | 9 | 11 |
| 2009 | 10 | 6 | 16 |
| 2010 | 7 | 6 | 13 |
| 2011 | 6 | 3 | 9 |
| 2012 | 10 | 13 | 23 |
| 2013 | 15 | 14 | 29 |
| 2014 | 23 | 11 | 34 |
| 2015 | 25 | 6 | 31 |
| 2016 | 25 | 10 | 35 |
| 2017 | 27 | 21 | 48 |
| 2018 | 17 | 16 | 33 |
| 2019 | 26 | 11 | 37 |
| 2020 | 27 | 8 | 35 |
| 2021 | 23 | 6 | 29 |
| 2022 | 31 | 1 | 32 |
| 2023 | 2 | 0 | 2 |
Below are the most recent publications written about "Metformin" by people in Profiles.
-
Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies. PLoS One. 2023; 18(1):e0276423.
-
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study. Nutrients. 2023 Jan 03; 15(1).
-
Metformin use and associated risk of total joint replacement in patients with type 2 diabetes: a population-based matched cohort study. CMAJ. 2022 12 19; 194(49):E1672-E1684.
-
Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia. Nat Commun. 2022 Dec 10; 13(1):7652.
-
Using the IMEDS distributed database for epidemiological studies in type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2022 12; 10(6).
-
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin. Ann Intern Med. 2022 12; 175(12):W155.
-
Metformin alleviates bone loss in ovariectomized mice through inhibition of autophagy of osteoclast precursors mediated by E2F1. Cell Commun Signal. 2022 10 25; 20(1):165.
-
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metab. 2023 01; 25(1):293-301.
-
COVID-19 outcomes in patients taking cardioprotective medications. PLoS One. 2022; 17(10):e0275787.
-
Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 11; 102(5):974-989.